Autonomic Manifestations of Testosterone Deficiency in Men

Status Withdrawn

Clinical Trial Summary

The primary goal of this pilot study is to investigate the association between testosterone deficiency and the presence of abnormalities in the function of the autonomic nervous system. If such association exists, then we will investigate the effect of testosterone replacement therapy on correcting these abnormalities.

Clinical Trial Description

The investigators will recruit 40 men between the ages of 40 to 80-years-old with low testosterone. Participants will be selected among those males referred to the Texas Tech University Health Sciences Center's (TTUHSC's) Internal Medicine Endocrinology Division outpatient clinic for the study and management of testosterone deficiency and to the TTUHSC Urology Department for diagnosis and management of prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.

After recruitment, patients will have an initial standard clinical visit where aspects such as fatigue and anxiety will be investigated, followed by a full battery of autonomic testing (tilt table, heart rate response to deep breathing, Valsalva, and the Quantitative Sudomotor Axon Reflex Test (QSART).

Those patients with an initial diagnosis of testosterone deficiency will be initiated on testosterone replacement (intramuscular or skin routes) as standard of care, followed by a second visit in three (3) months--after normalization of serum testosterone levels--to evaluate changes in anxiety and fatigue level, and to repeat the cardiovascular autonomic function test.

Those patients with primary diagnosis of prostate cancer and normal serum testosterone levels will be evaluated a second time after confirmation of low testosterone, as described above. Standard questionnaires will be used to evaluate fatigue and anxiety. The autonomic testing of the heart will include tilt table (tilt the patient 70 degree by special designed table) and heart rate response to deep breathing, and Valsalva maneuver. Descriptive statistics will be compared between before and after treatment using different statistical methods. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02715713
Study type	Observational
Source	Texas Tech University Health Sciences Center
Contact
Status	Withdrawn
Phase	N/A
Start date	March 2016
Completion date	August 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01446042` - Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism	Phase 3
Completed	`NCT02966652` - Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism	Phase 1
Completed	`NCT01228071` - Time to Eugonadal Range, Time to Steady State and Drying Time	Phase 3
Completed	`NCT00858650` - Registry of Hypogonadism in Men	N/A
Recruiting	`NCT05541172` - Testosterone Undecanoate Replacement Therapy in Boys With Pubertal Delay or Confirmed Hypogonadism
Not yet recruiting	`NCT04704141` - Relationship of the Microenvironment and Male Fertility
Completed	`NCT01403116` - Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men	Phase 3
Completed	`NCT00911586` - Pharmacokinetic Study to Determine Time to Steady-state	Phase 2
Completed	`NCT00924612` - Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation	Phase 2
Completed	`NCT01765179` - Safety and Efficacy Trial of Testosterone Undecanoate	Phase 3
Completed	`NCT00475501` - 5-Alpha Reductase and Anabolic Effects of Testosterone	Phase 2
Completed	`NCT04708249` - D-chiroinositol Administration in Hypogonadal Males	N/A
Completed	`NCT02081300` - Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism	Phase 3
Active, not recruiting	`NCT03721497` - Testosterone in Bariatric Patients	Phase 4
Completed	`NCT01699178` - Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.